IP Library Granted Patent US 12691148
Granted Patent B2
US 12691148 · App. 17/888,317 · Granted Jul 28, 2026

Use of probiotics in the treatment and/or prevention of atopic dermatitis

Inventors: Vicente Manuel Navarro López (Onil, ES); Ana Adela Ramírez Boscá (Alicante, ES); José Manuel Pérez Orquín (Alcoy, ES); Daniel Ramón Vidal (La Eliana, ES); Salvador Genovés Martínez (Aldaia, ES); María Empar Chenoll Cuadros (La Pobla de Vallbona, ES); Francisco Manuel Codoñer Cortés (Catarroja, ES)
Assignees: BIONOU RESEARCH, S.L.; BIOPOLIS, S.L.
A61K35/745A23L33/135A61K9/0019A61K35/747A61P17/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12691148
App. No.
17/888,317
Filed
Aug 15, 2022
Granted
Jul 28, 2026
Kind
B2
Art Unit
1653
USPC
424/93.4
Abstract

The present invention is intended for the use of a probiotic composition comprising Bifidobacterium animalis subs. lactis ( B. lactis ), Bifidobacterium longum and Lactobacillus casei , particularly the strains B. lactis CECT 8145, B. longum CECT 7347 and/or L. casei CECT 9104, in the treatment and/or prevention of atopic dermatitis.

Claims (11)

1 . A method for the treatment of atopic dermatitis comprising administering to a subject in need thereof an effective amount of a probiotic composition comprising a therapeutically effective amount of Bifidobacterium animalis subsp. lactis ( B. lactis ), Bifidobacterium longum and Lactobacillus casei,

wherein B. lactis is B. lactis CECT 8145, B. longum is B. longum CECT 7347 and L. casei is L. casei CECT 9104,

wherein B. longum concentration is 35% with respect to the total concentration of microorganisms present in the composition; B. lactis concentration is 35% with respect to the total concentration of microorganisms; and L. casei concentration is 30% with respect to the total concentration of microorganisms; and

wherein the total concentration of microorganisms of the strains B. lactis, L. casei and B. longum in the composition is from 10 7 to 10 8 cfu.

2 . The method according to claim 1 wherein the probiotic composition is a pharmaceutical composition or a nutritional composition.

3 . The method according to claim 2 wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier and/or an excipient.

4 . The method according to claim 2 , wherein the pharmaceutical composition is formulated for administration in liquid form or in solid form.

5 . The method according to claim 4 , wherein the solid form is selected from the group consisting of tablets, lozenges, chewable tablets, chewing gum, capsules, sachets, powders, granules, coated particles, coated tablets, tablets, gastro-resistant tablets, capsules, strips and dispersible films.

6 . The method according to claim 4 , wherein the liquid form is selected from the group consisting of oral solutions, suspensions, emulsions and syrups.

7 . The method according to claim 2 , wherein the nutritional composition is a food or a nutritional supplement.

8 . The method according to claim 7 , wherein the food is selected from the group consisting of fruit juices, vegetable juices, ice cream, infant formula, milk, yogurt, cheese, fermented milk, milk powder, cereals, baked goods, milk-based products, meat products and beverages.